The Long Run with Luke Timmerman

David Baltimore, professor emeritus at Caltech, reflects on a life in science.

Tony Kulesa of Petri.bio on fostering founder-led biotech companies

Christian Henry, CEO of PacBio, on long read DNA sequencing applications.

Keolu Fox, assistant professor at UC San Diego, on genome sequencing of indigenous populations.

Mara Aspinall of Arizona State University on diagnostics and COVID-19.

John Evans, CEO of Beam Therapeutics, on base editing technology for therapeutics.

Ep96: Julie Grant and Sam Blackman on Cancer Drugs for Kids

Sue Desmond-Hellmann on becoming a physician-scientist and biotech industry leader.

Jenny Rooke of Genoa Ventures on investing in biology & technology.

Ep93: Jay Bradner of Novartis & Andy Plump of Takeda on Mentoring Young Scientists

NanoString Technologies CEO Brad Gray on tools for spatial biology.

Daphne Zohar, CEO of Puretech Health, on starting biotech companies.

James Sabry, global head of pharma partnering for Roche, on partnering in a time of scientific abundance.

Emily Leproust, co-founder and CEO of Twist Bioscience, on DNA Synthesis at Scale

Amy DuRoss, CEO of Vineti, on software and logistics for cell and gene therapy.

Bob Nelsen of ARCH Venture Partners on long-term trends in biotech investing.

Sekar Kathiresan, co-founder and CEO of Verve Therapeutics, on a gene edited single shot for cardiovascular disease.

Luhan Yang, CEO of Qihan Bio, on CRISPR editing for organ transplants.

Steve Paul, CEO of Karuna Therapeutics, on neuropsychiatric drug development.

David Lee, CEO of Servier Pharma, on a nonprofit model.

Andrew Farnum, CEO of Variant Bio, on drug discovery based on rare genetic traits.

Simba Gill, CEO of Evelo Biosciences, on microbiome therapies.

Peter Kolchinsky of RA Capital on making drugs affordable, and keeping incentives for drug discovery.

Daphne Koller, CEO of insitro, on machine learning for drug discovery

Pearl Huang, CEO of Cygnal Therapeutics, on Exoneural Cancer Biology

Jennifer Petter, CSO of Arrakis Therapeutics, on small molecule drugs for RNA targets

Otello Stampacchia on becoming a biotech venture capitalist.

Rosana Kapeller, CEO of ROME Therapeutics

Abe Ceesay, CEO of Tiburio Therapeutics

Ep73: Kevin Ness on Digital Genome Engineering by Timmerman Report

Ted Love, CEO of Global Blood Therapeutics, on Racial Inequity

Takeda R&D president Andy Plump on fighting COVID19 and racism.

Nina Kjellson forging a path in biotech venture capital.

Ep69 of The Long Run with virologist Larry Corey

Emma Hodcroft on NextStrain and viral evolution

George Scangos of VIR on neutralizing antibodies for SARS-CoV-2

Mike Pellini on COVID19 diagnostic testing.

Leaders of EQRx, a company aspiring to make novel drugs at low prices.

Isabella is a Stage 4 lung cancer patient on a mission.

Jeremy Levin, chairman of BIO, on the perilous moment in politics.

Jane Grogan, CSO of Arsenal Bio, on programmable cell therapies.

Sanjiv Patel, CEO of Relay Therapeutics, computational drug discovery company.

Tim Mayleben, CEO of Esperion Therapeutics, on cholesterol-lowering meds.

David Baker, University of Washington protein designer.

Jigar Raythatha of Constellation Pharma on epigenetic drug development.

John Alam on Alzheimer's drug development.

Tim Springer of Harvard Medical School on his career in science and biotech.

Discussion on the new Henri Termeer biography.

CEO of Synlogic on developing synthetic biology-based drugs.

MIT biologist Phil Sharp on his early career.